Bluebird Lays Some New Eggs, But They'll Take Time To Hatch

Management outlined four new oncology and one rare disease program during an analyst day. CEO Nick Leschly also talked to Scrip about staying focused on R&D as other gene therapy players get bought out.

Eastern bluebird eggs in a nest on a blue background - Image

While bluebird bio Inc. is gearing up to launch its first commercial drug – the gene therapy Zynteglo for transfusion-dependent beta-thalassemia (TDT) – shortly in Europe, the company is building out its pipeline with a focus on immuno-oncology and rare diseases.

Bluebird held an analyst day in New York City on 9 May to highlight commercial plans for Zynteglo (previously LentiGlobin)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies